BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung CancerSun Min Lim(Yonsei University), Sang-Yoon Lee(ABL Bio (South Korea))Clinical Cancer ResearchMay 30, 202310.1158/1078-0432.ccr-22-3901Cited by 72SaveCiteExport RISWatch citationsRelated PapersCONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non–Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy|Journal of Clinical Oncology|2024|57Lack of ROS1 Gene Rearrangement in Glioblastoma Multiforme|PLoS ONE|2015|6